DIRECT2 Study Demonstrates T2Candida’s Advantages over Current Diagnostic Testing
The DIRECT2 study finds strong, reliable performance of the T2Candida Panel on real patient samples:
T2Candida Panel detected 89% of confirmed infections across a large patient population (N=152).
T2Candida Panel detected almost twice as many confirmed infections as blood culture in patients receiving antifungal therapy. This indicates that the T2Candida Panel is a more effective diagnostic tool for patients treated with pre-emptive or empiric antifungal therapy.
The median time to detection of Candida by diagnostic blood cultures and subsequent species identification was 3.4 days. In comparison, the T2Candida Panel provides diagnostic results in an average time of 4.4 hours.